{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:30:41Z","timestamp":1778221841297,"version":"3.51.4"},"reference-count":115,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.beem.2019.101354","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T12:22:54Z","timestamp":1571919774000},"page":"101354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Metastatic pheochromocytoma and paraganglioma: Management of endocrine manifestations, surgery and ablative procedures, and systemic therapies"],"prefix":"10.1016","volume":"34","author":[{"given":"Sina","family":"Jasim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilo","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.beem.2019.101354_bib1","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101354_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1758-3284-2-23","article-title":"Malignant head and neck paragangliomas: is there an optimal treatment strategy?","volume":"2","author":"Moskovic","year":"2010","journal-title":"Head Neck Oncol"},{"issue":"6","key":"10.1016\/j.beem.2019.101354_bib3","first-page":"Ze01","article-title":"Familial cancers of head and neck region","volume":"11","author":"Venugopal","year":"2017","journal-title":"J\u00a0Clin Diagn Res"},{"issue":"3","key":"10.1016\/j.beem.2019.101354_bib4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2019.101354_bib5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrc3648","article-title":"Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity","volume":"14","author":"Dahia","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.beem.2019.101354_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and phaeochromocytoma: from genetics to personalized medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"10.1016\/j.beem.2019.101354_bib7","doi-asserted-by":"crossref","first-page":"E1813","DOI":"10.1210\/jc.2013-1653","article-title":"The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2","volume":"98","author":"Thosani","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2019.101354_bib8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.beem.2019.101354_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","article-title":"Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours","volume":"28","author":"Lam","year":"2017","journal-title":"Endocr Pathol"},{"issue":"4","key":"10.1016\/j.beem.2019.101354_bib10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0b013e318190d12e","article-title":"Observer variation in the application of the pheochromocytoma of the adrenal gland scaled score","volume":"33","author":"Wu","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.beem.2019.101354_bib11","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1530\/EJE-14-0113","article-title":"Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma","volume":"171","author":"Baudin","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2019.101354_bib12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11912-013-0320-x","article-title":"Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma","volume":"15","author":"Jimenez","year":"2013","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"10.1016\/j.beem.2019.101354_bib13","first-page":"731","article-title":"Malignant pheochromocytoma with cutaneous metastases presenting with hemolytic anemia and pyrexia of unknown origin","volume":"50","author":"Srinivasan","year":"2002","journal-title":"J\u00a0Assoc Physicians India"},{"issue":"10","key":"10.1016\/j.beem.2019.101354_bib14","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/RLU.0b013e3181ef0af1","article-title":"Malignant pheochromocytoma metastasis to the breast shown on I-123 MIBG scan","volume":"35","author":"Patel","year":"2010","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.1016\/j.beem.2019.101354_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.14791\/btrt.2018.6.e18","article-title":"Pheochromocytoma with brain metastasis: a extremely rare case in Worldwide","volume":"6","author":"Cho","year":"2018","journal-title":"Brain Tumor Res Treat"},{"issue":"2","key":"10.1016\/j.beem.2019.101354_bib16","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/107327481101800205","article-title":"Changing paradigms in the treatment of malignant pheochromocytoma","volume":"18","author":"Grogan","year":"2011","journal-title":"Cancer Control"},{"issue":"34","key":"10.1016\/j.beem.2019.101354_bib17","doi-asserted-by":"crossref","first-page":"8812","DOI":"10.1200\/JCO.2005.03.1484","article-title":"Genetic testing in pheochromocytoma or functional paraganglioma","volume":"23","author":"Amar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.beem.2019.101354_bib18","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono study): a European network for the study of adrenal tumors retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2019.101354_bib19","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","article-title":"Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma","volume":"268","author":"Roman-Gonzalez","year":"2018","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.beem.2019.101354_bib20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13139-015-0331-7","article-title":"Diagnostic performance of (68)Ga-DOTATATE PET\/CT, (18)F-FDG PET\/CT and (131)I-MIBG scintigraphy in mapping metastatic pheochromocytoma and paraganglioma","volume":"49","author":"Tan","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.beem.2019.101354_bib21","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.beem.2019.101354_bib22","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1210\/jc.2013-1907","article-title":"One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma","volume":"98","author":"Hescot","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.beem.2019.101354_bib23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11912-017-0643-0","article-title":"Treatment for malignant pheochromocytomas and paragangliomas: 5 years of progress","volume":"19","author":"Jimenez","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.beem.2019.101354_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mce.2015.06.027","article-title":"From Nf1 to Sdhb knockout: successes and failures in the quest for animal models of pheochromocytoma","volume":"421","author":"Lepoutre-Lussey","year":"2016","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.beem.2019.101354_bib25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3389\/fendo.2018.00277","article-title":"Treatment for patients with malignant pheochromocytomas and paragangliomas: a perspective from the hallmarks of cancer","volume":"9","author":"Jimenez","year":"2018","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2019.101354_bib26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MED.0000000000000330","article-title":"Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials","volume":"24","author":"Roman-Gonzalez","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"4","key":"10.1016\/j.beem.2019.101354_bib27","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/SLA.0000000000002671","article-title":"Preoperative 18F-FDG PET\/CT in pheochromocytomas and paragangliomas allows for precision surgery","volume":"269","author":"Nockel","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.beem.2019.101354_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/cen.13737","article-title":"Role of DOTATATE-PET\/CT in preoperative assessment of phaeochromocytoma and paragangliomas","author":"Gild","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"10","key":"10.1016\/j.beem.2019.101354_bib29","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s00259-016-3357-x","article-title":"PET\/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT\/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma","volume":"43","author":"Janssen","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"17","key":"10.1016\/j.beem.2019.101354_bib30","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1158\/1078-0432.CCR-14-2751","article-title":"Superiority of [68Ga]-DOTATATE PET\/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma","volume":"21","author":"Janssen","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.beem.2019.101354_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11071018","article-title":"Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 metaiodobenzylguanidine","volume":"11","author":"Jimenez","year":"2019","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.beem.2019.101354_bib32","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2019.101354_bib33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1530\/EJE-15-0456","article-title":"Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma","volume":"173","author":"Thosani","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2019.101354_bib34","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.beem.2019.101354_bib35","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1530\/EJE-13-0882","article-title":"Diagnosis of endocrine disease: biochemical diagnosis of phaeochromocytoma and paraganglioma","volume":"170","author":"van Berkel","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2019.101354_bib36","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/HJH.0000000000001236","article-title":"High prevalence of cardiac electric abnormalities in patients with phaeochromocytomas","volume":"35","author":"Berra","year":"2017","journal-title":"J\u00a0Hypertens"},{"issue":"20","key":"10.1016\/j.beem.2019.101354_bib37","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.jacc.2016.03.543","article-title":"Pheochromocytoma is characterized by catecholamine-mediated myocarditis, focal and diffuse myocardial fibrosis, and myocardial dysfunction","volume":"67","author":"Ferreira","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.beem.2019.101354_bib38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1755-3768.2012.02394.x","article-title":"Small intraretinal haemorrhage as the initial manifestation of pheochromocytoma","volume":"91","author":"Rogers","year":"2013","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"10.1016\/j.beem.2019.101354_bib39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0736-4679(96)00241-7","article-title":"Pheochromocytoma and bowel ischemia","volume":"15","author":"Salehi","year":"1997","journal-title":"J\u00a0Emerg Med"},{"issue":"50","key":"10.1016\/j.beem.2019.101354_bib40","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002198","article-title":"Acute and chronic pheochromocytoma-induced cardiomyopathies: different prognoses?: a systematic analytical review","volume":"94","author":"Batisse-Lignier","year":"2015","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.beem.2019.101354_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajem.2017.11.021","article-title":"Fulminant adrenergic myocarditis complicated by pulmonary edema, cardiogenic shock and cardiac arrest","volume":"36","author":"Rostoff","year":"2018","journal-title":"Am J Emerg Med"},{"issue":"4","key":"10.1016\/j.beem.2019.101354_bib42","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1053\/j.jvca.2017.02.023","article-title":"Perioperative management of pheochromocytoma","volume":"31","author":"Naranjo","year":"2017","journal-title":"J\u00a0Cardiothorac Vasc Anesth"},{"issue":"5","key":"10.1016\/j.beem.2019.101354_bib43","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1055\/s-0031-1299707","article-title":"Metastatic pheochromocytoma and paraganglioma: focus on therapeutics","volume":"44","author":"Plouin","year":"2012","journal-title":"Horm Metab Res"},{"issue":"3","key":"10.1016\/j.beem.2019.101354_bib44","first-page":"191","article-title":"Alpha blockade in preoperative preparation of patients with pheochromocytomas","volume":"87","author":"Kocak","year":"2002","journal-title":"Int Surg"},{"issue":"2","key":"10.1016\/j.beem.2019.101354_bib45","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/med.2610140204","article-title":"Alpha-adrenoceptors: recent developments","volume":"14","author":"Ruffolo","year":"1994","journal-title":"Med Res Rev"},{"key":"10.1016\/j.beem.2019.101354_bib46","first-page":"163","article-title":"Alpha 1-adrenoceptors: pharmacological subclassification and therapeutic applications","volume":"37","author":"Hieble","year":"1994","journal-title":"Proc West Pharmacol Soc"},{"issue":"1\u20132","key":"10.1016\/j.beem.2019.101354_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0163-7258(94)90058-2","article-title":"Alpha-adrenoceptors","volume":"61","author":"Ruffolo","year":"1994","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.beem.2019.101354_bib48","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.0954-6820.1982.tb00409.x","article-title":"Pharmacokinetic and dynamic aspects of alpha-adrenoceptor blockade in hypertension","volume":"665","author":"Seideman","year":"1982","journal-title":"Acta Med Scand Suppl"},{"issue":"7","key":"10.1016\/j.beem.2019.101354_bib49","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1249\/MSS.0b013e3181a21294","article-title":"Lippincott's illustrated reviews: pharmacology, 4th edition","volume":"41","author":"Pazdernik","year":"2009","journal-title":"Med Sci Sport Exerc"},{"issue":"2","key":"10.1016\/j.beem.2019.101354_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2010.03.032","article-title":"Comparison of two preoperative medical management strategies for laparoscopic resection of pheochromocytoma","volume":"76","author":"Weingarten","year":"2010","journal-title":"Urology"},{"issue":"Suppl. 7","key":"10.1016\/j.beem.2019.101354_bib51","doi-asserted-by":"crossref","first-page":"vii131","DOI":"10.1093\/annonc\/mds231","article-title":"Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Berruti","year":"2012","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.beem.2019.101354_bib52","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1248\/bpb.b16-01001","article-title":"Control of constipation in patients receiving CHOP or CHOP-like chemotherapy regimens for non-Hodgkin's lymphoma","volume":"40","author":"Hayashi","year":"2017","journal-title":"Biol Pharm Bull"},{"issue":"8","key":"10.1016\/j.beem.2019.101354_bib53","doi-asserted-by":"crossref","first-page":"999","DOI":"10.4158\/EP171914.RA","article-title":"The physiology behind diabetes mellitus in patients with pheochromocytoma: a review of the literature","volume":"23","author":"Mesmar","year":"2017","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.beem.2019.101354_bib54","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12020-009-9300-1","article-title":"Fatal hypoglycemia in malignant pheochromocytoma: direct glucose consumption as suggested by (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography imaging","volume":"37","author":"Habra","year":"2010","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.beem.2019.101354_bib55","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1245\/s10434-016-5739-5","article-title":"Surgical treatment of malignant pheochromocytoma and paraganglioma: retrospective case series","volume":"24","author":"Strajina","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.beem.2019.101354_bib56","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jamcollsurg.2013.04.027","article-title":"Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted?","volume":"217","author":"Ellis","year":"2013","journal-title":"J\u00a0Am Coll Surg"},{"issue":"6","key":"10.1016\/j.beem.2019.101354_bib57","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00259-017-3919-6","article-title":"Antitumor effects of radionuclide treatment using alpha-emitting meta-(211)At-astato-benzylguanidine in a PC12 pheochromocytoma model","volume":"45","author":"Ohshima","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.beem.2019.101354_bib58","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/cncr.26577","article-title":"Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience","volume":"118","author":"Ayala-Ramirez","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.beem.2019.101354_bib59","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","author":"van Hulsteijn","year":"2014","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2019.101354_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/cpph.32","article-title":"Overview of monoamine transporters","volume":"79","author":"Aggarwal","year":"2017","journal-title":"Curr Protoc Pharmacol"},{"issue":"11","key":"10.1016\/j.beem.2019.101354_bib61","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2165\/00002018-200730110-00004","article-title":"Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management","volume":"30","author":"Eisenhofer","year":"2007","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.beem.2019.101354_bib62","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12022-011-9188-1","article-title":"Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification","volume":"23","author":"Eisenhofer","year":"2012","journal-title":"Endocr Pathol"},{"issue":"10","key":"10.1016\/j.beem.2019.101354_bib63","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European association of nuclear medicine practice guideline\/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Taieb","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.beem.2019.101354_bib64","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.adro.2017.11.002","article-title":"External beam radiation therapy for advanced\/unresectable malignant paraganglioma and pheochromocytoma","volume":"3","author":"Breen","year":"2018","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"10.1016\/j.beem.2019.101354_bib65","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1055\/s-0032-1308992","article-title":"External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG","volume":"44","author":"Fishbein","year":"2012","journal-title":"Horm Metab Res"},{"issue":"5","key":"10.1016\/j.beem.2019.101354_bib66","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.amjoto.2015.06.004","article-title":"External-beam radiation therapy for malignant paraganglioma of the head and neck","volume":"36","author":"Gilbo","year":"2015","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.beem.2019.101354_bib67","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fonc.2014.00166","article-title":"External beam radiation therapy in treatment of malignant pheochromocytoma and paraganglioma","volume":"4","author":"Vogel","year":"2014","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.beem.2019.101354_bib68","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/hed.20885","article-title":"Definitive radiotherapy in the management of paragangliomas arising in the head and neck: a 35-year experience","volume":"30","author":"Hinerman","year":"2008","journal-title":"Head Neck"},{"issue":"8","key":"10.1016\/j.beem.2019.101354_bib69","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/hed.22976","article-title":"Jugular and vagal paragangliomas: systematic study of management with surgery and radiotherapy","volume":"35","author":"Suarez","year":"2013","journal-title":"Head Neck"},{"issue":"4","key":"10.1016\/j.beem.2019.101354_bib70","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1210\/jc.2012-4231","article-title":"Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma","volume":"98","author":"Ayala-Ramirez","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2019.101354_bib71","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1507\/endocrj.43.511","article-title":"Acutely exacerbated hypertension and increased inflammatory signs due to radiation treatment for metastatic pheochromocytoma","volume":"43","author":"Teno","year":"1996","journal-title":"Endocr J"},{"issue":"9","key":"10.1016\/j.beem.2019.101354_bib72","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jvir.2011.06.016","article-title":"Minimally invasive treatment of metastatic pheochromocytoma and paraganglioma: efficacy and safety of radiofrequency ablation and cryoablation therapy","volume":"22","author":"McBride","year":"2011","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"7","key":"10.1016\/j.beem.2019.101354_bib73","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2169\/internalmedicine.49.3061","article-title":"Malignant pheochromocytoma with liver metastasis treated by transcatheter arterial chemo-embolization (TACE)","volume":"49","author":"Hidaka","year":"2010","journal-title":"Intern Med"},{"issue":"4","key":"10.1016\/j.beem.2019.101354_bib74","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2169\/internalmedicine.38.349","article-title":"Malignant pheochromocytoma with multiple hepatic metastases treated by chemotherapy and transcatheter arterial embolization","volume":"38","author":"Takahashi","year":"1999","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.beem.2019.101354_bib75","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1507\/endocrj.53.59","article-title":"Transcatheter arterial embolization for the treatment of liver metastases in a patient with malignant pheochromocytoma","volume":"53","author":"Watanabe","year":"2006","journal-title":"Endocr J"},{"issue":"3","key":"10.1016\/j.beem.2019.101354_bib76","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s12020-017-1515-y","article-title":"Prevention of serious skeletal-related events by interventional radiology techniques in patients with malignant paraganglioma and pheochromocytoma","volume":"59","author":"Gravel","year":"2018","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.beem.2019.101354_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020195","article-title":"Efficacy and safety of ablative therapy in the treatment of patients with metastatic pheochromocytoma and paraganglioma","volume":"11","author":"Kohlenberg","year":"2019","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.beem.2019.101354_bib78","first-page":"S187","article-title":"Diagnosis and treatment of phaeochromocytoma with 131I-metaiodobenzylguanidine","volume":"2","author":"Fischer","year":"1984","journal-title":"J\u00a0Hypertens Suppl"},{"issue":"25","key":"10.1016\/j.beem.2019.101354_bib79","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.beem.2019.101354_bib80","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1210\/jc.2017-02030","article-title":"Phase 1 study of high-specific-activity I-131 MIBG for metastatic and\/or recurrent pheochromocytoma or paraganglioma","volume":"103","author":"Noto","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.beem.2019.101354_bib81","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/BF03348026","article-title":"The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients","volume":"20","author":"Loh","year":"1997","journal-title":"J\u00a0Endocrinol Investig"},{"issue":"3","key":"10.1016\/j.beem.2019.101354_bib82","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/bjc.2013.365","article-title":"Sequelae and survivorship in patients treated with (131)I-MIBG therapy","volume":"109","author":"Sze","year":"2013","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.beem.2019.101354_bib83","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jso.23196","article-title":"Radionuclide therapy of adrenal tumors","volume":"106","author":"Carrasquillo","year":"2012","journal-title":"J\u00a0Surg Oncol"},{"issue":"5","key":"10.1016\/j.beem.2019.101354_bib84","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00259-008-0715-3","article-title":"EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy","volume":"35","author":"Giammarile","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.beem.2019.101354_bib85","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12672-017-0284-7","article-title":"Controlling tumor progression with cyclophosphamide, vincristine, and dacarbazine treatment improves survival in patients with metastatic and unresectable malignant pheochromocytomas\/paragangliomas","volume":"8","author":"Asai","year":"2017","journal-title":"Horm Cancer"},{"issue":"Suppl_5","key":"10.1016\/j.beem.2019.101354_bib86","first-page":"v142","article-title":"Activity of temozolomide (TMZ) in patients (PTS) with malignant pheochromocytoma or paraganglioma (MPP): a mono-institutional retrospective study","volume":"28","author":"Lombardi","year":"2017","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.beem.2019.101354_bib87","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.beem.2019.101354_bib88","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/CAD.0000000000000570","article-title":"Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma","volume":"29","author":"Ferrara","year":"2018","journal-title":"Anti Cancer Drugs"},{"issue":"8","key":"10.1016\/j.beem.2019.101354_bib89","doi-asserted-by":"crossref","first-page":"L51","DOI":"10.1530\/ERC-17-0086","article-title":"SDHB mutation carriers with malignant pheochromocytoma respond better to CVD","volume":"24","author":"Fishbein","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.beem.2019.101354_bib90","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12022-011-9189-0","article-title":"Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma","volume":"23","author":"Favier","year":"2012","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.beem.2019.101354_bib91","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.beem.2019.101354_bib92","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.13995.1","article-title":"Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors","volume":"7","author":"Toledo","year":"2018","journal-title":"F1000Res"},{"issue":"11","key":"10.1016\/j.beem.2019.101354_bib93","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.beem.2019.101354_bib94","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","article-title":"A\u00a0phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial","volume":"120","author":"O'Kane","year":"2019","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.beem.2019.101354_bib95","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-017-1359-5","article-title":"Phase II trial of pazopanib in advanced\/progressive malignant pheochromocytoma and paraganglioma","volume":"57","author":"Jasim","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2019.101354_bib96","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.2147\/OTT.S100706","article-title":"Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"4","key":"10.1016\/j.beem.2019.101354_bib97","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2217\/ije-2016-0015","article-title":"Durable response to lenvatinib in progressive, therapy-refractory, metastatic paraganglioma","volume":"3","author":"Jasim","year":"2016","journal-title":"Int J Endocr Oncol"},{"issue":"12","key":"10.1016\/j.beem.2019.101354_bib98","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s40265-014-0265-x","article-title":"Cabozantinib: a review of its use in patients with medullary thyroid cancer","volume":"74","author":"Hoy","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.beem.2019.101354_bib99","series-title":"A\u00a0phase 2 clinical trial with cabozantinib for patients with malignant pheochromocytoma and paraganglioma: preliminary results","author":"Jimenez","year":"2017"},{"issue":"9604","key":"10.1016\/j.beem.2019.101354_bib100","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.beem.2019.101354_bib101","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/157488408784293705","article-title":"The molecular basis of class side effects due to treatment with inhibitors of the VEGF\/VEGFR pathway","volume":"3","author":"Roodhart","year":"2008","journal-title":"Curr Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.beem.2019.101354_bib102","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1530\/ERC-13-0101","article-title":"In\u00a0vivo and in\u00a0vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas","volume":"20","author":"Toledo","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"7627","key":"10.1016\/j.beem.2019.101354_bib103","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.beem.2019.101354_bib104","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2alpha antagonist in patients with previously treated advanced clear cell renal cell carcinoma","volume":"36","author":"Courtney","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.beem.2019.101354_bib105","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2159-8290.CD-13-0092","article-title":"Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor","volume":"3","author":"Killian","year":"2013","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.beem.2019.101354_bib106","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ccr.2013.04.018","article-title":"SDH mutations establish a hypermethylator phenotype in paraganglioma","volume":"23","author":"Letouze","year":"2013","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.beem.2019.101354_bib107","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2019.101354_bib108","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.humpath.2018.11.020","article-title":"Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas","volume":"86","author":"Leijon","year":"2019","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.beem.2019.101354_bib109","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2265.1995.tb01877.x","article-title":"Short-term effects of octreotide on blood pressure and plasma catecholamines and neuropeptide Y levels in patients with phaeochromocytoma: a placebo-controlled trial","volume":"42","author":"Plouin","year":"1995","journal-title":"Clin Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2019.101354_bib110","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.clon.2011.12.003","article-title":"Radionuclide therapy in neuroendocrine tumours: a systematic review","volume":"24","author":"Gulenchyn","year":"2012","journal-title":"Clin Oncol"},{"issue":"4","key":"10.1016\/j.beem.2019.101354_bib111","first-page":"334","article-title":"Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma","volume":"52","author":"Forrer","year":"2008","journal-title":"Q\u00a0J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.beem.2019.101354_bib112","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2019.101354_bib113","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/onc.2016.225","article-title":"Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer","volume":"36","author":"Chouaib","year":"2017","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.beem.2019.101354_bib114","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1062967","article-title":"Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism","volume":"5","author":"Labiano","year":"2016","journal-title":"Oncoimmunology"},{"issue":"5\u20136","key":"10.1016\/j.beem.2019.101354_bib115","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12672-017-0303-8","article-title":"Interferon-alpha treatment for disease control in metastatic pheochromocytoma\/paraganglioma patients","volume":"8","author":"Hadoux","year":"2017","journal-title":"Horm Cancer"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X19301058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X19301058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:56:21Z","timestamp":1761497781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X19301058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":115,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1521690X19301058"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2019.101354","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metastatic pheochromocytoma and paraganglioma: Management of endocrine manifestations, surgery and ablative procedures, and systemic therapies","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2019.101354","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101354"}}